Management of anemia in patients with congestive heart failure

American Journal of Hematology

Volumn 92, Issue 1, 2017, Pages 88-93

  Tim Goodnough, Lawrence ^a   Comin Colet, Josep ^b   Leal Noval, Santiago ^c   Ozawa, Sherri ^d   Takere, Jacqueline ^e   Henry, David ^f   Javidroozi, Mazyar ^d   Hohmuth, Benjamin ^g   Bisbe, Elvira ^h,i   Gross, Irwin ^j   Shander, Aryeh ^d,k  

^a STANFORD UNIVERSITY   (United States)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^e ASHP Pharmacy Residency Program   (United States)

^f PENNSYLVANIA HOSPITAL   (United States)

^g TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Hospital Mar   (Spain)

ⁱ HOSPITAL DEL MAR   (Spain)

^j Accumen LLC   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; CLINICAL EVALUATION; CLINICAL OUTCOME; CONGESTIVE HEART FAILURE; HUMAN; IRON DEFICIENCY; IRON THERAPY; MANAGED CARE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANEMIA, IRON-DEFICIENCY; BLOOD; COMPLICATION; HEART FAILURE; INTRAVENOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

IRON DERIVATIVE;

ANEMIA, IRON-DEFICIENCY; HEART FAILURE; HUMANS; INJECTIONS, INTRAVENOUS; IRON COMPOUNDS; PREVALENCE; TREATMENT OUTCOME;

EID: 85006295136     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24595     Document Type: Review

References (63)

1. Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol 2014;89:88–96.
2. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kid Int Suppl 2012;2:311–316.
3. Rodgers GM, Becker PS, Blinder M, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012;10:628–653.
4. Goodnough LT, Levy JH, Murphy MF. Concepts of blood transfusion in adults. Lancet 2013;381:1845–1854.
5. Parikh A, Natarajan S, Lipsitz SR, Katz SD. Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: Prevalence and associations with anemia and inflammation. Circ Heart Fail 2011;4:599–606.
6. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: An international pooled analysis. Am Heart J 2013;165:575–582.
7. Qaseem A, Humphrey LL, Fitterman N, et al. Treatment of anemia in patients with heart disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2013;159:770–779.
8. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2013;128:1810–1852.
9. Berry C, Poppe KK, Gamble GD, et al. Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. QJM 2016;109:377–382.
10. Yamauchi T, Sakata Y, Takada T, et al. Prognostic impact of anemia in patients with chronic heart failure- with special reference to clinical background: Report from the CHART-2 study. Circ J 2015;79:1984–1993.
11. Kajimoto K, Sato N, Takano T. Association between anemia, clinical features and outcome in patients hospitalized for acute heart failure syndromes. Eur Heart J Acute Cardiovasc Care 2015;4:568–576.
12. Caughey MC, Avery CL, Ni H, et al. Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance). Am J Cardiol 2014;114:1850–1854.
13. Mentz RJ, Greene SJ, Ambrosy AP, et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: Findings from the EVEREST trial. Circ Heart Fail 2014;7:401–408.
14. Waldum B, Westheim AS, Sandvik L, et al. Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian heart failure registry. J Am Coll Cardiol 2012;59:371–378.
15. Tang WH, Tong W, Jain A, et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2008;51:569–576.
16. Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol 2008;101:223–230.
17. Bansal N, Tighiouart H, Weiner D, et al. Anemia as a risk factor for kidney function decline in individuals with heart failure. Am J Cardiol 2007;99:1137–1142.
18. Garty M, Shotan A, Gottlieb S, et al. The management, early and one year outcome in hospitalized patients with heart failure: A national heart failure survey in Israel—HFSIS 2003. Isr Med Assoc J 2007;9:227–233.
19. Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: Results from COMET. Eur Heart J 2006;27:1440–1446.
20. Felker GM, Shaw LK, Stough WG, O'Connor CM. Anemia in patients with heart failure and preserved systolic function. Am Heart J 2006;151:457–462.
21. Van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: An analysis of the European heart failure pilot survey. Eur J Heart Fail 2014;16:103–111.
22. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006;48:1225–1227.
23. Toblli JE, Lombrana A, Duarte P, Di GF. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007;50:1657–1665.
24. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103–112.
25. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008;21:236–242.
26. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436–2448.
27. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J 2015;36:657–668.
28. Pisaniello AD, Wong DT, Kajani I, et al. Anaemia in chronic heart failure: More awareness is required. Intern Med J 2013;43:999–1004.
29. Tang WH, Tong W, Jain A, et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2008;51:569–576.
30. Charlot M, Torp-Pedersen C, Valeur N, et al. Anaemia and long term mortality in heart failure patients: A retrospective study. Open Cardiovasc Med J 2010;4:173–177.
31. Peterson PN, Magid DJ, Lyons EE, et al. Association of longitudinal measures of hemoglobin and outcomes after hospitalization for heart failure. Am Heart J 2010;159:81–89.
32. Silverberg DS, Schwartz D, Schwartz I, Ben Assa E. The missed opportunities to diagnose and treat iron deficiency in patients hospitalized with heart failure. Int J Cardiol 2013;168:2164–2166.
33. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006;48:2485–2489.
34. Abramov D, Cohen RS, Katz SD, et al. Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions. Am J Cardiol 2008;102:1069–1072.
35. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011–1023.
36. Van der Meer P, Lipsic E, Westenbrink BD, et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 2005;112:1743–1747.
37. Silverberg DS, Wexler D, Iaina A, et al. Anemia, chronic renal disease and congestive heart failure—The cardio renal anemia syndrome: The need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006;38:295–310.
38. Ebner N, Jankowska EA, Ponikowski P, et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int J Cardiol 2016;205:6–12.
39. Adams KF Jr, Pina IL, Ghali JK, et al. Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. Am Heart J 2009;158:965–971.
40. Allen LA, Anstrom KJ, Horton JR, et al. Relationship between anemia and health care costs in heart failure. J Card Fail 2009;15:843–849.
41. Solid CA, Foley RN, Gilbertson DT, Collins AJ. Anemia and cost in Medicare patients with congestive heart failure. Congest Heart Fail 2006;12:302.
42. Gaber R, Kotb NA, Ghazy M, et al. Tissue Doppler and strain rate imaging detect improvement of myocardial function in iron deficient patients with congestive heart failure after iron replacement therapy. Echocardiography 2012;29:13–18.
43. Finch CA, Miller LR, Inamdar AR, et al. Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J Clin Invest 1976;58:447–453.
44. Xu W, Barrientos T, Mao L, et al. Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Rep 2015;13:533–545.
45. Carson JL, Adamson JW. Iron deficiency and heart disease: Ironclad evidence? ASH Educ Book 2010;1:348–350.
46. Enjuanes C, Klip IT, Bruguera J, et al. Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. Int J Cardiol 2014;174:268–275.
47. Enjuanes C, Bruguera J, Grau M, et al. Iron status in chronic heart failure: Impact on symptoms, functional class and submaximal exercise capacity. Rev Esp Cardiol 2016;69:247–255.
48. Klip IT, Jankowska EA, Enjuanes C, et al. The additive burden of iron deficiency in the cardiorenal-anaemia axis: Scope of a problem and its consequences. Eur J Heart Fail 2014;16:655–662.
49. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010;116:4754–4761.
50. Ferrucci L, Semba RD, Guralnik JM, et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood 2010;115:3810–3816.
51. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis. Transfusion 2012;52:1584–1592.
52. Siu CW, Yeung CY, Lau CP, et al. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 2007;93:483–487.
53. Bregman DB, Morris D, Koch TA, et al. Hepcidin levels predict non-responsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013; 88:97–101.
54. Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2014;54:306–315.
55. Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 2015;126:1981–1989.
56. Comin-Colet J, Lainscak M, Dickstein K, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: A subanalysis of the FAIR-HF study. Eur Heart J 2013;34:30–38.
57. Ponikowski P, Filippatos G, Colet JC, et al. The impact of intravenous ferric carboxymaltose on renal function: An analysis of the FAIR-HF study. Eur J Heart Fail 2015;17:329–339.
58. Gutzwiller FS, Schwenkglenks M, Blank PR, et al. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: An analysis for the UK. Eur J Heart Fail 2012;14:782–790.
59. Comin-Colet J, Rubio-Rodriguez D, Rubio-Terres C, et al. A cost-effectiveness analysis of ferric carboxymaltose in patients with iron deficiency and chronic heart failure in Spain. Rev Esp Cardiol (Engl Ed) 2015;68:846–851.
60. Jankowska EA, von Haehling S, Anker SD, et al. Iron deficiency and heart failure: Diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013;34:816–829.
61. Mcdonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: Intravenous or oral?. Eur J Heart Fail 2015;17:248–262.
62. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 2016;37:2129–2200.
63. Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol 2008;101:223–230.